Document is current
Any future updates will be listed below
-
Authors
Xue, Chenhui
Qiao, Xiaochen
Wang, Wenxuan
Gao, Zhenwu
Chen, Xin
Yang, Xihua
Wang, Hui
Jing, Jiansheng
Feng, Haoyu
Zhang, Hui
Sun, Lin
Guan, Xiaoming
-
Funding
Funding for this research was provided by:
Fundamental Research Program of Shanxi Province (202303021211217)
Research and Innovation TeamProject for Scientific Breakthroughs at Shanxi Bethune Hospital (2024ZHANCHI10)
Natural Science Foundation of Shanxi Province (202403021211177)
- License Information
-
More Information
Article History
Received: 1 August 2025
Accepted: 16 December 2025
First Online: 31 December 2025
Declarations
:
: This article does not include any studies involving human participants conducted by any of the authors. The hUC-MSCs were purchased from Fuyuan Biotechnology (Fuyuan Biotechnology Co., Ltd. Shanghai, China), and HBMECs were purchased from Meisen Cell Technology (Meisen Cell Technology, Zhejiang, China). The original sources have confirmed that there was initial ethical approval for collection of these human cells, and that the donors had signed informed consent. All animal experiments were performed in accordance with the ARRIVE guidelines and approved by the Shanxi Provincial People’s Hospital Institutional Animal Care and Use Committee (Title: BMSC-Exos Repair Blood-Spinal Cord Barrier Disruption after Spinal Cord Injury through Regulation of ET1/ETR; Approval No. 89/2022; Date: March 29, 2022).
: Not applicable.
: The authors declare no competing interests.
